Zhongda'an: Wu Junye, the controlling shareholder, plans to reduce his holdings by no more than 2%

Big Pharma CCHT’s Domination Unlikely to Fade Soon Despite Official Bulk Buying

The producer of long-acting growth hormone acupunctures, vaccines and other drugs, looks set to offset the effects of so-called “centralized procurement” on its product prices with more aggressive expansion into private hospitals. So far, its monopoly appears unshakable, but with more competitors upping the stakes, how long will it last?

Unpacking China | Key Chinese Firms to Watch This Week （26/07/2026-01/08/2026）

Amid fast-paced changes that fill the business community with excitement, angst and trepidation, EqualOcean will publish a series of roundup articles to document the major events related to Chinese companies going global every week.

Mabwell Signs GCC Licensing Deal with Saudi Arabia’s SVAX for Aflibercept Biosimilar

Mabwell (Shanghai) Bioscience Co., Ltd.（迈威（上海）生物科技股份有限公司）has entered into a licensing agreement with Saudi Arabian biopharmaceutical company SVAX Inc. covering its aflibercept biosimilar, 9MW0813, in the Gulf Cooperation Council market.

CFMOTO’s Overseas Revenue More Than Quintuples in Five Years, Reaching 70% of 2025 Sales

Zhejiang CFMOTO Power Co., Ltd.（浙江春风动力股份有限公司）, the Hangzhou-based powersports manufacturer behind the CFMOTO brand, generated CNY 13.79 billion in overseas revenue in 2025, accounting for 69.8% of its total sales. The figure was up 27.6% from a year earlier and more than five times the CNY 2.555 billion the company recorded in overseas sales in 2020.

Momenta says it is first Chinese company with Germany-wide L4 testing permit

Momenta Global Limited（Momenta，初速度科技）said on July 29 that it had received authorization from Germany’s Federal Motor Transport Authority, or KBA, to test Level 4 autonomous-driving systems on urban roads across the country. The Hong Kong-listed company said it was the first Chinese enterprise to obtain a German L4 testing permit with nationwide urban-road coverage.